购物车0
产品总数：60950
| 中文名称 |
Itolizumab
|
|---|---|
| 中文别名 |
ITOLIZUMAB ( 伊利组单抗 );伊利组单抗
|
| 英文名称 |
Itolizumab
|
| 英文别名 |
ITOLIZUMAB (monoclonal antybody);Itolizumab;EQ 001
|
| Cas No. |
1116433-11-4
|
| 包装储存 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 产品详情 |
Itolizumab (Anti-Human CD6 Recombinant Antibody) 是一种人源化重组 抗 CD6 单克隆抗体 (MAb)，靶向 CD6 的细胞外 SRCR 远端结构域 1。Itolizumab 可减少 T 细胞增殖并抑制促炎细胞因子的产生，例如 INF-γ、TNFα 和 IL-6。Itolizumab 可用于银屑病、类风湿性关节炎 (RA)、COVID-19 的研究。
|
|---|---|
| 生物活性 |
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.
|
| IC50 & Target[1][2] |
CD6
|
| 体外研究(In Vitro) |
Itolizumab (100 μg/mL) inhibits T cell proliferation.Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs.Itolizumab (40 μg/mL) reduces CD26CD161+?CD8+?T cells during culture of PBMCs overnight.Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 体内研究(In Vivo) |
Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD). has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 参考文献 |
[1]. Saavedra D, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020 Nov 14;17(1):34. [2]. Loganathan S, et al. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031.
|
1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。
2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料，如有违反，将追究法律责任。
沪ICP备2023012080号 | 
沪公网安备31011402010657号
扫码关注公众号
产品使用指南
